Sunday 27 September 2026
Internal Reference Number: FOI_9510
Date Request Received: 03/07/2026 00:00:00
Date Request Replied To: 17/07/2026 00:00:00
This response was sent via: By Email
Request Summary: Diffuse Large B Cell Lymphoma (DLBCL)
Request Category: Private Individuals
| Question Number 1: In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? a. Of these patients, how many commenced treatment at your trust within the last 6 months? | |
| Answer To Question 1: 10 patients diagnosed and 6 commenced treatment within the last 6 months (Jan - June 2026). | |
| Question Number 2: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: • R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) • R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) • R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) • R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) • (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Axicabtagene ciloleucel • Tisagenlecleucel • Epcoritamab • Loncastuximab tesirine • Glofitamab • Any other SACT • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Glofitamab + GemOx (gemcitabine and oxaliplatin) | |
| Answer To Question 2: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: • R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) less than 5 • R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) less than 5 • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) less than 5 • Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) less than 5 • R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) 0 • R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)0 • R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) 0 • (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) 0 • R-GemOX (rituximab, gemcitabine and oxaliplatin) less than 5 • Axicabtagene ciloleucel 0 • Tisagenlecleucel 0 • Epcoritamab 0 • Loncastuximab tesirine 0 • Glofitamab 0 • Any other SACT less than 5 • Stem cell transplant or bone marrow transplant (autologous or allogeneic) 0 • Glofitamab + GemOx (gemcitabine and oxaliplatin) less than 5 | |
| Question Number 3: In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL): • Axicabtagene ciloleucel (Yescarta) • Tisagenlecleucel • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Glofitamab + GemOx (gemcitabine and oxaliplatin) • Any other treatments | |
| Answer To Question 3: • Axicabtagene ciloleucel (Yescarta) 0 • Tisagenlecleucel 0 • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) 0 • R-GemOX (rituximab, gemcitabine and oxaliplatin) 0 • Stem cell transplant or bone marrow transplant (autologous or allogeneic) 0 • Glofitamab + GemOx (gemcitabine and oxaliplatin) less than 5 • Any other treatments 0 | |
| Question Number 4: In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)? | |
| Answer To Question 4: 0 | |
| Question Number 5: . In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments: • CAR-T Therapy (E.g. Axicabtagene ciloleucel) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Any other treatment | |
| Answer To Question 5: 0 patients referred elsewhere | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
